loading page

Systemic Bevacizumab for Recurrent Respiratory Papillomatosis
  • Yiressy Izaguirre Baday,
  • Julina Ongkasuwan,
  • Rajkumar Venkatramani
Yiressy Izaguirre Baday
Baylor College of Medicine

Corresponding Author:baday@bcm.edu

Author Profile
Julina Ongkasuwan
Baylor College of Medicine
Author Profile
Rajkumar Venkatramani
Texas Children's Hospital
Author Profile


Recurrent respiratory papillomatosis (RRP) is a benign tumor of the respiratory tract associated with human papillomavirus types 6 and 11. Patients undergo multiple surgical debridements for management of rapidly growing papilloma. Adjuvant treatment options for management of RRP in children are often ineffective and do not decrease the need for repeated surgical debridement. We report on three patients initially treated with 10 mg/kg systemic bevacizumab every 4 weeks. All patients had improvement in voice and reduced need for surgical debridement. The interval between bevacizumab doses was gradually increased to every 8-12 weeks. Adverse events included mild proteinuria and self-resolving epistaxis.
Nov 2020Published in International Journal of Pediatric Otorhinolaryngology volume 138 on pages 110352. 10.1016/j.ijporl.2020.110352